Novel systemic therapy options for hepatocellular carcinoma

Mike Cusnir, Yehuda Z. Patt

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Hepatocellular carcinoma, a common malignancy globally, has been increasing in incidence in the United States, mostly due to the rising incidence of Hepatitis C viral (HCV) infection. The prognosis of patients with this cancer has been poor and even tumor resection has rarely been curative. However, orthotopic liver transplantation (OLT) has been associated with long-term survival benefit and cures, provided rigorous patient-selection criteria were adhered to. Liver cirrhosis is the most common precursor for HCC, and attempts have been made to prevent the progression from liver cirrhosis to HCC. Post resection adjuvant therapies have included interferon, polyprenoic acid, and adoptive immunotherapy. Finding effective systemic treatments for non-resectable HCC has been challenging and quite frustrating. The presence of liver cirrhosis and the associated volume expansion, electrolyte imbalances, decreased liver synthetic and metabolic reserve, and portal hypertension has made the design of systemic therapy for HCC a major challenge. Additionally staging of HCC using the Tumor Node Metastases (TNM) system, but ignoring the underlying liver disease made it extremely difficult to compare results of different trials. However by and large it would seem, that the more aggressive chemotherapy agents and combinations were associated with median survival times of 3-5 months. Considering the vascular nature of HCC it may be reasonable to combine tolerable chemotherapy with newly released agents with angiogenesis inhibiting properties. Thus, systemic therapy of HCC is a work in progress that calls for additional trials of tolerable newer agents and combinations.

Original languageEnglish
Pages (from-to)97-103
Number of pages7
JournalCancer Journal
Volume10
Issue number2
DOIs
StatePublished - Mar 1 2004
Externally publishedYes

Fingerprint

Hepatocellular Carcinoma
Liver Cirrhosis
Patient Selection
Neoplasms
Adoptive Immunotherapy
Survival
Incidence
Portal Hypertension
Virus Diseases
Therapeutics
Hepatitis C
Combination Drug Therapy
Liver Transplantation
Interferons
Electrolytes
Blood Vessels
Liver Diseases
Neoplasm Metastasis
Drug Therapy
Liver

Keywords

  • Cirrhosis
  • Hepatocellular carcinoma
  • Liver transplantation
  • Systemic therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Novel systemic therapy options for hepatocellular carcinoma. / Cusnir, Mike; Patt, Yehuda Z.

In: Cancer Journal, Vol. 10, No. 2, 01.03.2004, p. 97-103.

Research output: Contribution to journalArticle

Cusnir, Mike ; Patt, Yehuda Z. / Novel systemic therapy options for hepatocellular carcinoma. In: Cancer Journal. 2004 ; Vol. 10, No. 2. pp. 97-103.
@article{9d7067562d134953a88e73db7a2e2783,
title = "Novel systemic therapy options for hepatocellular carcinoma",
abstract = "Hepatocellular carcinoma, a common malignancy globally, has been increasing in incidence in the United States, mostly due to the rising incidence of Hepatitis C viral (HCV) infection. The prognosis of patients with this cancer has been poor and even tumor resection has rarely been curative. However, orthotopic liver transplantation (OLT) has been associated with long-term survival benefit and cures, provided rigorous patient-selection criteria were adhered to. Liver cirrhosis is the most common precursor for HCC, and attempts have been made to prevent the progression from liver cirrhosis to HCC. Post resection adjuvant therapies have included interferon, polyprenoic acid, and adoptive immunotherapy. Finding effective systemic treatments for non-resectable HCC has been challenging and quite frustrating. The presence of liver cirrhosis and the associated volume expansion, electrolyte imbalances, decreased liver synthetic and metabolic reserve, and portal hypertension has made the design of systemic therapy for HCC a major challenge. Additionally staging of HCC using the Tumor Node Metastases (TNM) system, but ignoring the underlying liver disease made it extremely difficult to compare results of different trials. However by and large it would seem, that the more aggressive chemotherapy agents and combinations were associated with median survival times of 3-5 months. Considering the vascular nature of HCC it may be reasonable to combine tolerable chemotherapy with newly released agents with angiogenesis inhibiting properties. Thus, systemic therapy of HCC is a work in progress that calls for additional trials of tolerable newer agents and combinations.",
keywords = "Cirrhosis, Hepatocellular carcinoma, Liver transplantation, Systemic therapy",
author = "Mike Cusnir and Patt, {Yehuda Z.}",
year = "2004",
month = "3",
day = "1",
doi = "10.1097/00130404-200403000-00005",
language = "English",
volume = "10",
pages = "97--103",
journal = "Cancer journal (Sudbury, Mass.)",
issn = "1528-9117",
publisher = "Association Pour le Developpement de la Communication Cancerologique",
number = "2",

}

TY - JOUR

T1 - Novel systemic therapy options for hepatocellular carcinoma

AU - Cusnir, Mike

AU - Patt, Yehuda Z.

PY - 2004/3/1

Y1 - 2004/3/1

N2 - Hepatocellular carcinoma, a common malignancy globally, has been increasing in incidence in the United States, mostly due to the rising incidence of Hepatitis C viral (HCV) infection. The prognosis of patients with this cancer has been poor and even tumor resection has rarely been curative. However, orthotopic liver transplantation (OLT) has been associated with long-term survival benefit and cures, provided rigorous patient-selection criteria were adhered to. Liver cirrhosis is the most common precursor for HCC, and attempts have been made to prevent the progression from liver cirrhosis to HCC. Post resection adjuvant therapies have included interferon, polyprenoic acid, and adoptive immunotherapy. Finding effective systemic treatments for non-resectable HCC has been challenging and quite frustrating. The presence of liver cirrhosis and the associated volume expansion, electrolyte imbalances, decreased liver synthetic and metabolic reserve, and portal hypertension has made the design of systemic therapy for HCC a major challenge. Additionally staging of HCC using the Tumor Node Metastases (TNM) system, but ignoring the underlying liver disease made it extremely difficult to compare results of different trials. However by and large it would seem, that the more aggressive chemotherapy agents and combinations were associated with median survival times of 3-5 months. Considering the vascular nature of HCC it may be reasonable to combine tolerable chemotherapy with newly released agents with angiogenesis inhibiting properties. Thus, systemic therapy of HCC is a work in progress that calls for additional trials of tolerable newer agents and combinations.

AB - Hepatocellular carcinoma, a common malignancy globally, has been increasing in incidence in the United States, mostly due to the rising incidence of Hepatitis C viral (HCV) infection. The prognosis of patients with this cancer has been poor and even tumor resection has rarely been curative. However, orthotopic liver transplantation (OLT) has been associated with long-term survival benefit and cures, provided rigorous patient-selection criteria were adhered to. Liver cirrhosis is the most common precursor for HCC, and attempts have been made to prevent the progression from liver cirrhosis to HCC. Post resection adjuvant therapies have included interferon, polyprenoic acid, and adoptive immunotherapy. Finding effective systemic treatments for non-resectable HCC has been challenging and quite frustrating. The presence of liver cirrhosis and the associated volume expansion, electrolyte imbalances, decreased liver synthetic and metabolic reserve, and portal hypertension has made the design of systemic therapy for HCC a major challenge. Additionally staging of HCC using the Tumor Node Metastases (TNM) system, but ignoring the underlying liver disease made it extremely difficult to compare results of different trials. However by and large it would seem, that the more aggressive chemotherapy agents and combinations were associated with median survival times of 3-5 months. Considering the vascular nature of HCC it may be reasonable to combine tolerable chemotherapy with newly released agents with angiogenesis inhibiting properties. Thus, systemic therapy of HCC is a work in progress that calls for additional trials of tolerable newer agents and combinations.

KW - Cirrhosis

KW - Hepatocellular carcinoma

KW - Liver transplantation

KW - Systemic therapy

UR - http://www.scopus.com/inward/record.url?scp=4544265216&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4544265216&partnerID=8YFLogxK

U2 - 10.1097/00130404-200403000-00005

DO - 10.1097/00130404-200403000-00005

M3 - Article

C2 - 15130269

AN - SCOPUS:4544265216

VL - 10

SP - 97

EP - 103

JO - Cancer journal (Sudbury, Mass.)

JF - Cancer journal (Sudbury, Mass.)

SN - 1528-9117

IS - 2

ER -